Expect a negative stock reaction as the market prices in the loss of a major pipeline asset. Monitor for analyst downgrades of Novartis's net present value (NPV) for pelacarsen and any potential write-downs related to the Ionis license. The full data presentation at an upcoming medical congress may provide further detail on subgroup analyses.
Price Chart
Executive Summary
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide targeting elevated lipoprotein(a), did not meet the primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established CVD. Despite achieving lower Lp(a) levels, the drug failed to translate biomarker reduction into clinical benefit, eliminating a major pipeline opportunity in a large unmet cardiovascular market.
Key Facts
- Pelacarsen Phase III Lp(a)HORIZON trial (NCT04023552) did not meet its primary composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.
- Trial enrolled 8,323 patients with elevated Lp(a) (≥70 mg/dL) and established CVD; lower Lp(a) levels were achieved but did not reduce cardiovascular risk.
- Novartis obtained global rights to pelacarsen under a license and collaboration agreement with Ionis Pharmaceuticals.
- Elevated Lp(a) affects approximately 20% of the global population with no approved targeted treatment.
Financial Impact
Failure of a high-profile Phase III cardiovascular outcomes trial eliminates a significant future revenue opportunity for Novartis; no specific financial figures provided in the filing.
Risk Factors
- Potential impairment of intangible assets related to the pelacarsen license from Ionis Pharmaceuticals.
- Loss of future revenue stream from a drug targeting a large unmet cardiovascular need.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005896 |
| Document: 0001171843-26-005896-index-headers.html | 0001171843-26-005896 |
| Document: 0001171843-26-005896-index.html | 0001171843-26-005896 |
| Document: 0001171843-26-005896.txt | 0001171843-26-005896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 6-K | $137.70 $138.62 | ▼ −0.67% | ▼ −1.79% | $140.21 (−1.82%) |
Sep 1, 2026 4w ago | 6-K | $161.25 $137.48 | ▼ −14.74% | ▼ −14.82% | $140.21 (−13.05%) |
Aug 4, 2026 8w ago | Court Ruling | $153.27 $154.61 | ▲ +0.87% | ▲ +0.97% | $140.21 (−8.52%) |
Jul 28, 2026 9w ago | Court Ruling | $159.85 $153.67 | ▼ −3.87% | ▼ −6.14% | $140.21 (−12.29%) |
Jul 21, 2026 10w ago | 6-K | $153.87 $156.11 | ▲ +1.46% | ▲ +2.68% | $140.21 (−8.88%) |
Jul 1, 2026 13w ago | Court Ruling | $154.14 $157.03 | ▼ −1.87% | ▼ −1.61% | $140.21 (+9.04%) |
Apr 30, 2026 22w ago | Court Ruling | $147.85 $148.36 | ▼ −0.34% | ▲ +1.38% | $140.21 (+5.17%) |
Apr 14, 2026 24w ago | Court Ruling | $153.38 $147.97 | ▲ +3.53% | ▲ +4.92% | $140.21 (+8.59%) |
Mar 30, 2026 26w ago | Court Ruling | $150.36 $151.22 | ▲ +0.57% | ▼ −3.73% | $140.21 (−6.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access